Notably, treatment-induced tumor volume reduction correlated with decreased levels of CCL-2, CCL-7, and CCL-12 and increased levels of CXCL-10, CCL-24, CXCL-12, and IL-3. The gene discussed is CCL2; the disease is neoplasm.